Company Encyclopedia
View More
name
Nus Esg Lrgc Grw
NULG.US
News
View More

Brookstone Capital Management Has $35.35 Million Stock Holdings in Eli Lilly and Company $LLY

Brookstone Capital Management increased its holdings in Eli Lilly and Company by 10.9% in Q3, now owning 46,325 shares valued at $35.35 million. Eli Lilly's stock opened at $1,077.06, with a market cap of $1.02 trillion. The company reported Q3 earnings of $7.02 per share, surpassing estimates, and increased its dividend to $1.73. Analysts have given the stock a consensus rating of "Moderate Buy."

Market Beat·
US
LLY
+0.50%
Market Beat·
US
LLY
+0.50%

Avanza Fonder AB Buys 4,555 Shares of Mastercard Incorporated $MA

Avanza Fonder AB increased its stake in Mastercard by 8.1% in the third quarter, purchasing an additional 4,555 shares, making it the firm's 15th largest holding. Mastercard's stock is valued at $34,592,000 in Avanza's portfolio. Other institutional investors also adjusted their positions in Mastercard. Analysts have given the stock a consensus rating of 'Buy' with a target price of $657.48. Mastercard's recent earnings exceeded expectations, with a quarterly revenue increase of 16.7% year-over-year.

Market Beat·
US
MA
+0.54%
Market Beat·
US
MA
+0.54%

Chamath Palihapitiya Looks Set To Make A Windfall From Nvidia's Purchase Of Groq, Here Is What The SPAC King Said After The Deal

Chamath Palihapitiya is set for a significant financial gain following NVIDIA's $20.6 billion acquisition of Groq. Palihapitiya's Social Capital was an early investor in Groq, holding close to one-third ownership. Despite dilution from later funding rounds, the investment is expected to deliver substantial returns. Palihapitiya highlighted his early involvement with Groq and predicted a $100 billion valuation by 2045. Groq will remain independent, with its founder and team joining Nvidia to advance technology licensing.

benzinga_article·
US
NVDA
-0.32%
benzinga_article·
US
NVDA
-0.32%

As India’s US$70 million obesity drug market bulges, so does price war

Global pharmaceutical giants Eli Lilly and Novo Nordisk are competing in India's growing obesity drug market, which is expected to exceed US$1 billion within two years. Lilly's Mounjaro and Novo's Wegovy are leading the market, with Novo cutting prices to compete. Over 20 Indian drug makers plan to launch cheaper generics by 2026. The market is expanding beyond urban elites to middle-class families and smaller towns. Lilly has partnered with Cipla and Apollo Hospitals to increase reach.

南华早报·
US
LLY
+0.50%
US
NVO
+1.84%
南华早报·
US
LLY
+0.50%
US
NVO
+1.84%

NVIDIA Stock Crosses $190 On Robinhood Overnight Trading After Groq Deal

NVIDIA shares climbed to $190.16 in overnight trading following the company's $20 billion licensing agreement with AI chip startup Groq.

benzinga_article·
US
NVDA
-0.32%
US
NVDL
-0.57%
HK
07788
+5.38%
benzinga_article·
US
NVDA
-0.32%
US
NVDL
-0.57%
HK
07788
+5.38%
© 2025 Longbridge｜Disclaimer